$KYNB Income Statement | Understand Stock

$KYNB

$4.65 -$0.07 (1.48%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
License Revenue
Development and Other Revenue
Product Revenue, Net
Drug Product Revenue, Net
Total revenue
Operating costs and expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Restructuring charge
Total operating costs and expenses
Loss from operations
Interest and other, net
Interest expense
Loss on debt extinguishments
Interest income and other income (expenses), net
Total interest and other, net
Loss from continuing operations before income taxes
Benefit from income taxes
Share of Net Income
Loss from continuing operations
Income from discontinued operations, net of tax
Net income (loss)
Net loss per share - basic and diluted
Weighted average number of common shares used to calculate net loss per share - basic and diluted
Loss from continuing operations per share - basic
Loss from continuing operations per share - diluted
Income from discontinued operations per share - basic
Income from discontinued operations per share - diluted
Net income (loss) per share - basic
Net income (loss) per share - diluted
Weighted average number of common shares used to calculate net income (loss) per share:
Basic
Diluted

Comments